Ryan Preblick Sells 36,000 Shares of Indivior (NASDAQ:INDV) Stock

Indivior PLC (NASDAQ:INDV) CFO Ryan Preblick sold 36,000 shares of Indivior stock in a transaction on Monday, June 8th. The stock was sold at an average price of $37.70, for a total transaction of $1,357,200.00. Following the transaction, the chief financial officer directly owned 284,751 shares of the company’s stock, valued at $10,735,112.70. The trade was a 11.22% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Indivior Trading Up 0.1%

Indivior stock opened at $38.13 on Friday. The firm has a 50-day moving average price of $35.28 and a 200-day moving average price of $34.27. The firm has a market capitalization of $4.65 billion, a PE ratio of 19.55 and a beta of 0.88. Indivior PLC has a 12-month low of $13.45 and a 12-month high of $41.00.

Indivior (NASDAQ:INDV) last issued its quarterly earnings results on Tuesday, March 31st. The company reported $0.96 EPS for the quarter. The company had revenue of $317.00 million for the quarter. Indivior had a net margin of 19.44% and a negative return on equity of 219.26%. As a group, sell-side analysts predict that Indivior PLC will post 4.05 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Indivior

A number of institutional investors have recently modified their holdings of the stock. Quarry LP bought a new position in Indivior in the third quarter worth approximately $26,000. Raymond James Financial Inc. bought a new stake in Indivior during the 2nd quarter valued at $26,000. Salomon & Ludwin LLC bought a new stake in Indivior during the 4th quarter valued at $30,000. Harbor Capital Advisors Inc. lifted its holdings in shares of Indivior by 309.9% in the 4th quarter. Harbor Capital Advisors Inc. now owns 1,033 shares of the company’s stock worth $37,000 after buying an additional 781 shares during the period. Finally, Caitong International Asset Management Co. Ltd increased its stake in shares of Indivior by 72.7% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,093 shares of the company’s stock valued at $39,000 after buying an additional 460 shares during the period. 60.33% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on INDV shares. Zacks Research raised Indivior from a “hold” rating to a “strong-buy” rating in a research note on Monday, March 16th. Weiss Ratings lowered Indivior from a “hold (c+)” rating to a “hold (c)” rating in a research note on Wednesday, May 6th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Indivior has an average rating of “Buy” and an average target price of $39.33.

Indivior Company Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.